Market Place
Sourcing Support
Orsini Distributes CASGEVY® Gene-Editing Therapy
14 Nov 2024 //
PR NEWSWIRE
Vertex`s Casgevy breaks ground with 1st commercial infusions
05 Nov 2024 //
FIERCE PHARMA
Vertex Reports Third Quarter 2024 Financial Results
04 Nov 2024 //
BUSINESSWIRE
Vertex to Participate in Upcoming November Investor Conferences
29 Oct 2024 //
BUSINESSWIRE
Undaunted Vertex closes in on FDA nod for non-opioid pain drug
28 Oct 2024 //
FIERCE BIOTECH
Vertex Updates on Kidney Programs at ASN Annual Kidney Week
25 Oct 2024 //
BUSINESSWIRE
Rectify drug repairs bile composition in mice with liver disease
22 Oct 2024 //
FIERCE BIOTECH
Vertex pain data: Combo results, Vicodin miss and stellar safety
21 Oct 2024 //
FIERCE BIOTECH
Vertex To Present Phase 3 Data On Suzetrigine At ASA Meeting
18 Oct 2024 //
BUSINESSWIRE
Vertex To Announce Q3 2024 Results On November 4th
10 Oct 2024 //
BUSINESSWIRE
Vertex survey delves into current difficulties in pain treatment
10 Oct 2024 //
FIERCE PHARMA
Editas cashes in on Vertex Cas9 licensing agreement for $57M
04 Oct 2024 //
FIERCE BIOTECH
Vertex Presents CF Data At North American Conference
26 Sep 2024 //
BUSINESSWIRE
LinkedIn Post Lands Vertex In Hot Water With MHRA Over UK Ad Regulations
22 Aug 2024 //
FIERCE PHARMA
UK`s NHS To Roll Out Vertex/CRISPR Gene Therapy For Rare Blood Disorder
08 Aug 2024 //
REUTERS
US Q2 earnings growth estimate dips, reflecting Vertex loss, LSEG says
03 Aug 2024 //
REUTERS
Vertex lifts sales guidance as Casgevy launch picks up
03 Aug 2024 //
FIERCE PHARMA
Vertex, beaten by rare disease again, drops 2 assets on growing discard pile
01 Aug 2024 //
FIERCE BIOTECH
Vertex Raises Forecast On Strong Cystic Fibrosis Treatment Demand
01 Aug 2024 //
REUTERS
FDA Accepts Vertex`s NDA For Suzetrigine For Moderate-To-Severe Acute Pain
29 Jul 2024 //
PRESS RELEASE
Vertex mines for more gene editing riches with $15M Orum licensing deal
17 Jul 2024 //
FIERCE BIOTECH
Orum Therapeutics And Vertex Sign Multi-Target License Agreement
16 Jul 2024 //
BUSINESSWIRE
Genomics Plc Expands Drug Discovery Collaboration With Vertex
16 Jul 2024 //
PR NEWSWIRE
Vertex sues US over fertility support program for Casgevy gene editing therapy
16 Jul 2024 //
REUTERS
FDA Accepts Vertex`s NDA For Next-Gen Cystic Fibrosis Treatment
02 Jul 2024 //
BUSINESSWIRE
Vertex to Announce Second Quarter 2024 Financial Results on August 1
01 Jul 2024 //
BUSINESSWIRE
Vertex inks long-term access deal for CF meds in Englan
22 Jun 2024 //
FIERCE PHARMA
Long-term data shows durability of Vertex`s gene therapy Casgevy
14 Jun 2024 //
FIERCE PHARMA
Vertex to Participate in Upcoming June Investor Conferences
22 May 2024 //
BUSINESSWIRE
Jennifer Schneider Elected to Vertex Board of Directors
15 May 2024 //
BUSINESSWIRE
Tessera unveils promising in vivo gene editing for sickle cell in #ASGCT24
10 May 2024 //
ENDPTS
With 64 centers activated, bluebird is ready to grow Lyfgenia
09 May 2024 //
FIERCE PHARMA
Vertex touts Casgevy sickle cell launch as bluebird makes progress Lyfgenia
06 May 2024 //
ENDPTS
Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
06 May 2024 //
REUTERS
Vertex Reports First Quarter 2024 Financial Results
06 May 2024 //
BUSINESSWIRE
Vertex: EU Approval for KALYDECO® in Infants ?1 Month with CF
26 Apr 2024 //
BUSINESSWIRE
As pharma eyes shiny obesity drugs, Vertex tops orphan drug list
24 Apr 2024 //
FIERCE BIOTECH
Vertex licenses TreeFrog’s tech to upscale cell therapy Mfg for diabetes
23 Apr 2024 //
PRESS RELEASE
Vertex announces advancements of pain signal inhibitor, suzetrigine
20 Apr 2024 //
PHARMABIZ
Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications
19 Apr 2024 //
ENDPTS
Vertex begins bid for US approval of non-opioid painkiller
19 Apr 2024 //
BIOPHARMADIVE
Vertex Updates On Suzetrigine For Acute And Neuropathic Pain
18 Apr 2024 //
BUSINESSWIRE
Vertex to Announce First Quarter 2024 Financial Results on May 6
09 Apr 2024 //
BUSINESSWIRE
Vertex Pharmaceuticals is considering relocating its headquarters
26 Mar 2024 //
STAT NEWS
Vertex Announces FDA Clearance of NDA for VX-407 for the Treatment of ADPKD
21 Mar 2024 //
BUSINESSWIRE
UK`s NICE says it`s not ready to recommend Vertex`s Casgevy for sickle cell
15 Mar 2024 //
ENDPTS
Vertex Receives CHMP Positive Opinion for KALYDECO® for Cystic Fibrosis
23 Feb 2024 //
BUSINESSWIRE
Vertex to Participate in Upcoming Investor Conferences
20 Feb 2024 //
BUSINESSWIRE
The $100 billion club gets a shakeup, driven by biotech’s new blue-chip names
20 Feb 2024 //
ENDPTS
Vertex`s sales of Trikafta hit $8.9B thanks to label expansion
06 Feb 2024 //
FIERCE PHARMA
Vertex meets own cystic fibrosis record with next-gen treatment
06 Feb 2024 //
FIERCE BIOTECH
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
05 Feb 2024 //
BUSINESSWIRE
Vertex non-opioid painkiller meets main goal in late-stage trials
31 Jan 2024 //
REUTERS
Vertex Announces Positive Results From the VX-548 Phase 3 Program
30 Jan 2024 //
BUSINESSWIRE
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results
17 Jan 2024 //
PRESS RELEASE
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
17 Jan 2024 //
REUTERS
Saudi Arabia approves first CRISPR/Cas9 gene-edited therapy
12 Jan 2024 //
BIOSPECTRUM ASIA
Vertex founder Joshua Boger on surviving downturns, `painful` partnerships
12 Jan 2024 //
ENDPTS
Vertex cuts ties to CRISPR’s type 1 diabetes stem cell therapy
08 Jan 2024 //
FIERCE BIOTECH
Vertex Provides Pipeline and Business Updates
07 Jan 2024 //
BUSINESSWIRE
